Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3196 | Standard of Care (SoC) Wiki | 0.58 |
drug686 | Camostat Mesilate Wiki | 0.32 |
drug899 | Convalescent plasma Wiki | 0.21 |
Name (Synonyms) | Correlation | |
---|---|---|
D012120 | Respiration Disorders NIH | 0.22 |
D012140 | Respiratory Tract Diseases NIH | 0.20 |
D003141 | Communicable Diseases NIH | 0.07 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This study is a 4-arm, multicenter, randomized, partly double- blind, controlled trial to evaluate the safety and efficacy of convalescent serum (CP) or camostat mesylate with control or placebo in adult patients diagnosed with SARS-CoV-2 and high risk for moderate/severe COVID-19. The working hypothesis to be tested in the RES-Q-HR study is that the early use of convalescent plasma (CP) or camostat mesylate (Foipan®) reduces the likelihood of disease progression to modified WHO stages 4b-8 in SARS-CoV-2 positive adult patients at high risk of moderate or severe COVID-19 progression. The primary endpoint of the study is the cumulative number of individuals who progressed to or beyond category 4b on the modified WHO (World Health Organization) COVID-19 ordinal scale within 28 days after randomization.
Description: The primary endpoint of the study is the number of individuals whose clinical status is on the COVID-19 modified WHO ordinal scale ≥ 4b up to and including day 28
Measure: WHO ordinal Covid-19 scale up to day 28 Time: up to and including day 28Description: Cumulative number of persons in the respective treatment arms versus SoC/placebo in WHO categories 4b-8
Measure: Cumulative number WHO categories 4b-8 Time: day 8, day 14, day 56 and day 90Description: Cumulative number of persons in the respective treatment arms versus SoC/placebo in WHO categories 3-4a
Measure: Cumulative number WHO categories 3-4a Time: day 8, day 14, day 28, day 56 and day 90Description: Cumulative number of participants not hospitalized at day 90
Measure: Not hospitalized Time: at day 90Description: All-cause mortality at day 90
Measure: All-cause mortality Time: at day 90Description: Number of patient with SARS-CoV-2 reinfection up to day 90
Measure: Reinfection Time: up to day 90Description: Number of patient with secondary sclerosis cholangitis at day 90
Measure: Secondary sclerosing cholangitis (SSC) Time: at day 90Description: Number of patient with COVID-19 associated chronic pulmonary disease
Measure: chronic pulmonary disease as sequelae from COVID-19 Time: at day 90Description: The proportion of patients with remdesivir therapy
Measure: patients with remdesivir treatment Time: up to day 90Description: The clinical status on the WHO COVID-19 ordinal scale of at the start of remdesivir treatment WHO ordinal scale ranges from 0 to 8; whereas 0 = no COVID-19 infection and 8 = death
Measure: COVID-19 WHO status of patients at start of remdesivir treatment Time: up to day 90Description: The proportion of patients on dexamethasone therapy
Measure: patients with dexamethasone treatment Time: up to day 90Description: The clinical status on the WHO COVID-19 ordinal scale of at the start of dexamethasone treatment WHO ordinal scale ranges from 0 to 8; whereas 0 = no COVID-19 infection and 8 = death
Measure: COVID-19 WHO status of patients at start of dexamethasone treatment Time: up to day 90Description: Time to resolution of COVID-19 related symptoms (e.g. fever)
Measure: resolution of COVID-19 symptoms Time: until day of resolution up to day 90Description: Time to first negative SARS-CoV-2-PCR (polymerase chain reaction)
Measure: negative SARS-CoV-2-PCR test Time: until day of first negative test up to day 90Description: Duration of oxygen therapy (in days)
Measure: Oxygen therapy Time: number of days with oxygen therapy up to day 90Description: Frequency of occurrence of COVID-19 pneumonia
Measure: COVID-19 pneumonia Time: up to day 90Description: Percentage of participants in each group with need for mechanical ventilation
Measure: Percentage of participants requiring mechanical ventilation Time: up to day 90Description: Number of ventilation days per participant up to day 90
Measure: Number of ventilation days per participant up to day 90 Time: up to day 90Description: Duration of hospital stay (in days), duration in intensive care/intermediate care (IMC) (in days)
Measure: hospital stay and intensive care Time: up to day 90Description: All-cause mortality at day 28
Measure: Mortality Time: at day 28Description: Cumulative incidence of Serious Adverse Events (SAE) per group within 90 days follow up
Measure: SAEs Time: up to day 90Description: Cumulative incidence of grade 3/4 Adverse Events (AE) per group
Measure: Grade 3/4 AEs Time: up to day 90Description: SARS-CoV-2 antibody concentrations (IgA in g/l) in serum on day 8, day 14, day 90
Measure: SARS-CoV-2 antibody IgA concentrations Time: on day 8, day 14, day 90Description: SARS-CoV-2 antibody concentrations (IgG in g/l) in serum on day 8, day 14, day 90
Measure: SARS-CoV-2 antibody IgG concentrations Time: on day 8, day 14, day 90Description: SARS-CoV-2 neutralizing antibody titers in serum on day 8, day 14, day 90
Measure: SARS-CoV-2 neutralizing antibody titers Time: on day 8, day 14, day 90Description: Number of screening failures due to the lack of a suitable plasma preparation
Measure: Plasma treatment screening failures Time: up to day 8 (End of treatment)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports